Drotrecogin alfa (activated): down and not out, but not really in either.
作者信息
Friedrich Jan O, Adhikari Neill K J, Meade Maureen O
出版信息
Crit Care. 2006;10(5):420. doi: 10.1186/cc5022.
Abstract
摘要
相似文献
1
Drotrecogin alfa (activated): down and not out, but not really in either.重组人活化蛋白C：虽未一蹶不振，但也未真正站稳脚跟。
Crit Care. 2006;10(5):420. doi: 10.1186/cc5022.
2
A case series of drotrecogin alfa (activated) in lung transplant recipients.
Transplantation. 2006 Jun 27;81(12):1739-42. doi: 10.1097/01.tp.0000226077.87011.87.
3
Drotrecogin alfa (activated) in severe sepsis.重组人活化蛋白C用于严重脓毒症治疗
Med Sci Monit. 2004 Oct;10(10):LE19. Epub 2004 Sep 23.
4
Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated).接受活化蛋白C治疗的严重脓毒症患者医院死亡率的预测因素。
Pharmacotherapy. 2005 Jan;25(1):26-34. doi: 10.1592/phco.25.1.26.55615.
5
Drotrecogin alfa (activated) in the treatment of severe sepsis.
Expert Rev Anti Infect Ther. 2006 Aug;4(4):537-47. doi: 10.1586/14787210.4.4.537.
6
Meeting unmet needs in patients with sepsis: the role of drotrecogin alfa (activated).满足脓毒症患者未被满足的需求：活化蛋白C的作用。
Am J Crit Care. 2003 Sep;12(5):398; author reply 398.
7
Introduction: severe sepsis and drotrecogin alfa (activated).
Crit Care. 2007;11 Suppl 5:S1. doi: 10.1186/cc6180.
8
Drotrecogin alfa (activated) in severe sepsis.
N Engl J Med. 2006 Jan 5;354(1):94-6; author reply 94-6.
9
Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results.活化蛋白C：再审视。更多针对严重脓毒症的临床试验：大多为阴性结果。
Prescrire Int. 2007 Feb;16(87):7-9.
10
Drotrecogin alfa (activated) in severe sepsis.
N Engl J Med. 2006 Jan 5;354(1):94-6; author reply 94-6.
引用本文的文献
1
Activated protein C in sepsis: the promise of nonanticoagulant activated protein C.脓毒症中的活化蛋白C：非抗凝活化蛋白C的前景
Curr Opin Hematol. 2008 Sep;15(5):487-93. doi: 10.1097/MOH.0b013e32830abdf4.
2
Why are clinicians not embracing the results from pivotal clinical trials in severe sepsis? A bayesian analysis.为何临床医生不接受严重脓毒症关键临床试验的结果？一项贝叶斯分析。
PLoS One. 2008 May 28;3(5):e2291. doi: 10.1371/journal.pone.0002291.
3
How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? A Bayesian design.需要多少例严重脓毒症患者才能证实活化蛋白C（drotrecogin alfa）的疗效？一项贝叶斯设计。
Intensive Care Med. 2008 Oct;34(10):1804-11. doi: 10.1007/s00134-008-1159-8. Epub 2008 May 27.
4
Drotrecogin alfa (activated) in patients with severe sepsis and a high risk of death.严重脓毒症且死亡风险高的患者使用活化蛋白C。
Crit Care. 2006;10(6):427. doi: 10.1186/cc5117.
本文引用的文献
1
Activated protein C in sepsis: down but not out, yet.脓毒症中的活化蛋白C：虽已式微，但尚未出局。
Crit Care. 2006;10(4):416. doi: 10.1186/cc4988.
2
Drotrecogin alfa (activated): does current evidence support treatment for any patients with severe sepsis?活化蛋白C：目前的证据是否支持对任何严重脓毒症患者进行治疗？
Crit Care. 2006;10(3):145. doi: 10.1186/cc4947. Epub 2006 Jun 2.
3
Prescription of rh-APC differs substantially among western European countries.重组人活化蛋白C（rh-APC）在西欧各国的处方差异很大。
Intensive Care Med. 2006 Apr;32(4):630-1. doi: 10.1007/s00134-006-0075-z. Epub 2006 Mar 7.
4
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death.重组人活化蛋白C用于严重脓毒症且死亡风险较低的成人患者。
N Engl J Med. 2005 Sep 29;353(13):1332-41. doi: 10.1056/NEJMoa050935.
5
Drotrecogin alfa (activated) administration: too many subgroups.重组人活化蛋白C的给药：亚组过多。
Crit Care Med. 2003 Oct;31(10):2564; author reply 2564-5. doi: 10.1097/01.CCM.0000089929.73924.4C.
6
Measuring inconsistency in meta-analyses.评估荟萃分析中的异质性
BMJ. 2003 Sep 6;327(7414):557-60. doi: 10.1136/bmj.327.7414.557.
7
Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis.重组人活化蛋白C在严重脓毒症患者重要临床亚组中的应用。
Crit Care Med. 2003 Jan;31(1):12-9. doi: 10.1097/00003246-200301000-00002.
8
Efficacy and safety of recombinant human activated protein C for severe sepsis.重组人活化蛋白C治疗严重脓毒症的疗效与安全性
N Engl J Med. 2001 Mar 8;344(10):699-709. doi: 10.1056/NEJM200103083441001.
Zotero 插件